FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.777,70 +733,58 (+1,24%)
Liquidia Corporation (LQDA)
Dopo ore:
| Chiusura precedente | 12,98 |
| Aperto | 13,15 |
| Denaro | 12,77 x 200 |
| Lettera | 12,81 x 200 |
| Min-Max giorno | 12,66 - 13,22 |
| Intervallo di 52 settimane | 5,71 - 16,99 |
| Volume | |
| Media Volume | 848.070 |
| Capitalizzazione | 976,935M |
| Beta (5 anni mensile) | 0,19 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,21 |
| Prossima data utili | 02 mag 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 25,14 |
GlobeNewswireEmergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent’s 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. “Neal and Don bring unique and extensive expertise to Emergent as the company defines
GlobeNewswireFDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s amendment to the tentatively approved new drug application (NDA) for YUTREPIA™ (treprostinil) inhalation powder in which the Company is seeking to add the treatment of pulmonary h
- GlobeNewswire
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTAB) MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company), announced today that United Therapeutics Corporation (UTHR) filed a patent infringement action under the Hatch-Waxman Act in the U.S.
